FATE Fate Therapeutics, Inc. Stock Quote

FATE [NASD]

Index	-	P/E	-	EPS (ttm)	-2.44	Insider Own	1.40%	Shs Outstand	96.34M	Perf Week	-0.08%
Market Cap	2.06B	Forward P/E	-	EPS next Y	-3.77	Insider Trans	-22.90%	Shs Float	95.31M	Perf Month	-33.12%
Income	-232.80M	PEG	-	EPS next Q	-0.83	Inst Own	-	Short Float	17.37%	Perf Quarter	-37.35%
Sales	63.10M	P/S	32.72	EPS this Y	-6.40%	Inst Trans	1.03%	Short Ratio	11.87	Perf Half Y	-55.83%
Book/sh	6.57	P/B	3.61	EPS next Y	-28.50%	ROA	-24.60%	Target Price	86.26	Perf Year	-69.59%
Cash/sh	6.59	P/C	3.60	EPS next 5Y	-	ROE	-33.30%	52W Range	20.49 - 97.43	Perf YTD	-59.44%
Dividend	-	P/FCF	-	EPS past 5Y	-16.30%	ROI	-32.00%	52W High	-75.64%	Beta	1.76
Dividend %	-	Quick Ratio	7.70	Sales past 5Y	66.20%	Gross Margin	-	52W Low	15.81%	ATR	2.79
Employees	449	Current Ratio	7.70	Sales Q/Q	65.80%	Oper. Margin	-	RSI (14)	37.50	Volatility	11.22% 10.41%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-41.30%	Profit Margin	-	Rel Volume	0.84	Prev Close	22.64
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 04 AMC	Payout	-	Avg Volume	1.39M	Price	23.73
Recom	1.70	SMA20	-18.07%	SMA50	-29.88%	SMA200	-53.82%	Volume	1,177,554	Change	4.81%

Feb-11-22

Resumed

BMO Capital Markets

Market Perform

$50

Dec-15-21

Upgrade

Wedbush

Neutral → Outperform

Dec-07-21

Initiated

Cowen

Outperform

Nov-09-21

Upgrade

Citigroup

Neutral → Buy

$94 → $87

Aug-26-21

Initiated

Morgan Stanley

Equal-Weight

$77

Jun-07-21

Upgrade

H.C. Wainwright

Neutral → Buy

$120

May-07-21

Upgrade

Wedbush

Neutral → Outperform

$88

Apr-26-21

Resumed

Jefferies

Buy

$145

Feb-26-21

Initiated

BofA Securities

Buy

$115

Feb-26-21

Downgrade

Wedbush

Outperform → Neutral

Feb-11-21

Downgrade

Citigroup

Buy → Neutral

Jan-27-21

Resumed

H.C. Wainwright

Neutral

$108

May-13-20

Initiated

H.C. Wainwright

Buy

$42

Mar-04-20

Initiated

Barclays

Overweight

$40

Jan-09-20

Downgrade

BMO Capital Markets

Outperform → Market Perform

$22

Dec-30-19

Reiterated

Mizuho

Buy

$27 → $33

Dec-09-19

Upgrade

Wells Fargo

Market Perform → Outperform

Nov-12-19

Initiated

SunTrust

Buy

$25

Nov-06-19

Downgrade

Wells Fargo

Outperform → Market Perform

Oct-01-19

Initiated

Stifel

Buy

$27

May-09-22 07:32AM	While Fate Therapeutics (NASDAQ:FATE) shareholders have made 502% in 5 years, increasing losses might now be front of mind as stock sheds 15% this week Simply Wall St. -7.49%
May-06-22 04:01PM	Fate Therapeutics to Present at Upcoming May Investor Conferences GlobeNewswire -11.14%
May-05-22 10:18AM	FATE's Loss Narrower Than Expected in Q1, Pipeline in Focus Zacks -11.40%
May-04-22 05:15PM	Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates Zacks +6.64%
04:01PM	Fate Therapeutics Reports First Quarter 2022 Financial Results and Highlights Operational Progress GlobeNewswire
Apr-27-22 03:03PM	Analysts Estimate Fate Therapeutics (FATE) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-25-22 06:04PM	Nkarta Scores Huge Gain on Cancer Treatment Results GuruFocus.com
Apr-22-22 08:00AM	Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2022 Financial Results GlobeNewswire
Mar-30-22 11:30AM	Fate Therapeutics (FATE) Up 21.9% Since Last Earnings Report: Can It Continue? Zacks
Mar-02-22 04:01PM	Fate Therapeutics to Present at Upcoming March Investor Conferences GlobeNewswire
Mar-01-22 11:59AM	FATE's Loss Wider Than Expected in Q4, Pipeline in Focus Zacks
Feb-28-22 05:45PM	Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates Zacks
04:01PM	Fate Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Operational Progress GlobeNewswire
Feb-20-22 12:47AM	Top 10 Healthcare Stocks the Experts at Sphera Global Healthcare Fund Are Buying Insider Monkey
Feb-16-22 08:00AM	Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2021 Financial Results GlobeNewswire
Feb-06-22 03:52PM	Was The Smart Money Right About Fate Therapeutics Inc (FATE)? Insider Monkey
Feb-02-22 01:38PM	Emerald Advisers, Llc Buys Customers Bancorp Inc, Herc Holdings Inc, ACADIA Pharmaceuticals ... GuruFocus.com
08:00AM	Fate Therapeutics to Present at Upcoming February Investor Conferences GlobeNewswire
Jan-27-22 09:38AM	Brown Advisory Inc Buys Visa Inc, Alphabet Inc, Mastercard Inc, Sells Chegg Inc, Fair Isaac ... GuruFocus.com -8.89%
Jan-10-22 08:00AM	Fate Therapeutics Announces FDA Clearance for FT536, a First-in-class MICA/B-targeted CAR NK Cell Product Candidate for the Treatment of Solid Tumors GlobeNewswire
Dec-23-21 01:38PM	MainStay VP Small Cap Growth Portfolio Buys Option Care Health Inc, Leslies Inc, Kratos Defense ... GuruFocus.com
Dec-22-21 12:15AM	Fate Therapeutics Inc (FATE) CFO Edward J Dulac Iii Sold $958,620 of Shares GuruFocus.com
Dec-19-21 06:24PM	Cathie Wood Pours Money Into 3 Strong Buy Innovation Stocks TipRanks
Dec-17-21 11:38PM	VY(R) Invesco Oppenheimer Global Portfolio Buys Analog Devices Inc, Splunk Inc, Danaher Corp, ... GuruFocus.com +13.81%
Dec-14-21 07:35AM	Fate Therapeutics Showcases Interim Data From FT596 Cell Program In Lymphoma Benzinga
Dec-13-21 04:38PM	Invesco V.I. Global Fund Buys Analog Devices Inc, Dassault Systemes SE, Splunk Inc, Sells , ... GuruFocus.com
04:31PM	Fate Therapeutics Showcases Positive Interim Phase 1 Data from FT596 Off-the-shelf, iPSC-derived CAR NK Cell Program for Relapsed / Refractory B-cell Lymphoma at 2021 ASH Annual Meeting GlobeNewswire
09:01AM	Fate Therapeutics Highlights Positive Durability of Response Data from FT516 Phase 1 Study for B-cell Lymphoma and Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to FT516 for Relapsed / Refractory DLBCL GlobeNewswire
Dec-08-21 08:06PM	Hedge Funds Are Cashing Out Of Fate Therapeutics Inc (FATE) Insider Monkey
05:44PM	Fate Therapeutics to Host Virtual Event at the 2021 ASH Annual Meeting GlobeNewswire
Dec-01-21 08:00AM	Cathie Wood Likes Fate Therapeutics, Should You? Motley Fool -5.24%
Nov-25-21 05:57AM	3 Biotech Stocks That Can Double Your Money, According to Wall Street Motley Fool
Nov-11-21 08:00AM	Fate Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Nov-09-21 09:00AM	Fate Therapeutics Announces Abstract Highlighting FT538 and FT573 Programs Selected for Presentation at SITC 2021 Annual Meeting Press Conference GlobeNewswire
Nov-05-21 09:24AM	FATE's Q3 Loss Narrower Than Expected, Pipeline in Focus Zacks
Nov-04-21 05:15PM	Fate Therapeutics (FATE) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:01PM	Fate Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Operational Progress GlobeNewswire
09:01AM	Fate Therapeutics Announces Eight Presentations at the 2021 ASH Annual Meeting GlobeNewswire
Oct-28-21 03:06PM	Analysts Estimate Fate Therapeutics (FATE) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-25-21 08:00AM	Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2021 Financial Results GlobeNewswire
Oct-12-21 05:37AM	Hedge Funds Are Crazy About Fate Therapeutics Inc (FATE) Insider Monkey
Oct-01-21 08:01AM	Fate Therapeutics Announces Presentations at the Society for Immunotherapy of Cancer 2021 Annual Meeting GlobeNewswire
Sep-15-21 08:00AM	Fate Therapeutics Announces Publication of FT538 Preclinical Data Demonstrating Enhanced Serial Killing and Functional Persistence without Cytokine Support GlobeNewswire
Sep-14-21 08:19AM	Recent Poor Results Have Made This Promising Cathie Wood Pick a Bargain Motley Fool
Sep-03-21 11:31AM	Why Is Fate Therapeutics (FATE) Down 21% Since Last Earnings Report? Zacks
Sep-02-21 04:01PM	Fate Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Aug-26-21 07:36AM	We're Hopeful That Fate Therapeutics (NASDAQ:FATE) Will Use Its Cash Wisely Simply Wall St.
Aug-20-21 04:02PM	Fate Stock Collapses As Investors Question Durability Of Cancer 'Killers' Investor's Business Daily -21.74%
11:57AM	Why Fate Therapeutics Stock Is Sliding Today Motley Fool
06:36AM	Fate Therapeutics' Stem Cell-Derived NK Lymphoma Candidate Casts Doubt Over Durability Of Response Benzinga
05:54AM	Fate Therapeutics Stock Falls on Trial Data for Lymphoma Treatment TheStreet.com
Aug-19-21 04:01PM	Fate Therapeutics Announces Positive Interim Clinical Data from its FT596 and FT516 Off-the-shelf, iPSC-derived NK Cell Programs for B-cell Lymphoma GlobeNewswire -5.90%
Aug-15-21 11:05AM	The Week Ahead In Biotech: Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow Benzinga
Aug-06-21 04:31PM	Fate Therapeutics, inc (FATE) Q2 2021 Earnings Call Transcript Motley Fool
Aug-05-21 11:41AM	FATE Reports Wider-Than-Expected Q2 Loss, Beats on Revenues Zacks +11.44%
Aug-04-21 05:55PM	Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:01PM	Fate Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Operational Progress GlobeNewswire
Aug-02-21 04:50PM	Fate Therapeutics Announces Treatment of First Patient in Landmark Phase 1 Clinical Trial of FT819, the First-ever iPSC-derived CAR T-Cell Therapy GlobeNewswire
Jul-28-21 03:04PM	Earnings Preview: Fate Therapeutics (FATE) Q2 Earnings Expected to Decline Zacks +5.84%
Jul-22-21 11:40AM	Did You See What Cathie Wood Bought on Wednesday? Motley Fool
Jul-16-21 08:00AM	Fate Therapeutics to Host Virtual Event Highlighting Interim Phase 1 Clinical Data from its Off-the-Shelf, iPSC-derived NK Cell Franchise for B-cell Lymphoma GlobeNewswire
Jul-15-21 04:01PM	Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2021 Financial Results GlobeNewswire
Jun-28-21 09:31AM	Hedge Funds Have Never Been This Bullish On Fate Therapeutics Inc (FATE) Insider Monkey +5.41%
Jun-15-21 08:00AM	Fate Therapeutics Appoints Mark Plavsic, DVM, PhD, RAC as Chief Technical Officer GlobeNewswire
Jun-04-21 03:06PM	Fate Therapeutics Stock is Trading Higher on Positive B-Cell Lymphoma Data at ASCO21 Benzinga +8.24%
11:32AM	Why Is Fate Therapeutics (FATE) Down 12.2% Since Last Earnings Report? Zacks
07:00AM	Fate Therapeutics Highlights Positive Interim Data from its Phase 1 Study of FT516 in Combination with Rituximab for B-cell Lymphoma at 2021 ASCO Annual Meeting GlobeNewswire
Jun-02-21 09:40AM	10 Best Pharmaceutical Stocks to Buy According to Cathie Wood Insider Monkey
May-31-21 06:01AM	The Best Biotech Stocks to Buy With $500 Motley Fool
May-25-21 04:01PM	Fate Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
May-14-21 08:17AM	Fate Therapeutics' iPSC-Derived Cell Therapies Induce Leukemic Blast Clearance, Show Durable Remissions In AML Patients Benzinga +7.26%
May-13-21 04:01PM	Fate Therapeutics Announces Encouraging Interim Phase 1 Data for iPSC-derived NK Cell Programs in Relapsed / Refractory Acute Myeloid Leukemia GlobeNewswire
May-06-21 01:29PM	FATE Reports Wider-Than-Expected Q1 Loss, Beats on Revenues Zacks
11:01AM	Fate Therapeutics Inc (FATE) Q1 2021 Earnings Call Transcript Motley Fool
May-05-21 05:15PM	Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates Zacks
04:01PM	Fate Therapeutics Reports First Quarter 2021 Financial Results and Highlights Operational Progress GlobeNewswire
03:15PM	Fate Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Apr-29-21 08:00AM	Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2021 Financial Results GlobeNewswire -6.75%
Apr-27-21 04:31PM	Fate Therapeutics Announces Four Presentations at the 2021 ASGCT Annual Meeting GlobeNewswire
Apr-15-21 12:29PM	Natural Killer Cells and Other Promising Cancer Treatments Barrons.com
Apr-06-21 02:00PM	Is Fate Therapeutics Stock A Buy or Sell? Insider Monkey
Apr-02-21 06:20AM	3 of the Most Innovative Stocks to Buy Now Motley Fool
Mar-26-21 11:31AM	Fate Therapeutics (FATE) Down 9% Since Last Earnings Report: Can It Rebound? Zacks -8.10%
Mar-25-21 07:00AM	Fate Therapeutics Announces Retirement of Chief Scientific Officer after 12 Years of Service GlobeNewswire
05:55AM	2 Under-the-Radar Stocks Cathie Wood Loves That Could Be Huge Winners Motley Fool
Mar-08-21 07:00AM	Fate Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire -5.37%
Feb-27-21 09:23AM	15 Fastest Growing Biotech Companies in the US Insider Monkey
01:43AM	Fate Therapeutics, Inc. (NASDAQ:FATE) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates Simply Wall St.
Feb-25-21 12:48PM	FATE Reports Wider-Than-Expected Q4 Loss on Higher Expenses Zacks -9.45%
03:30AM	Fate Therapeutics Inc (FATE) Q4 2020 Earnings Call Transcript Motley Fool
Feb-24-21 04:55PM	Fate Therapeutics: Q4 Earnings Insights Benzinga
04:01PM	Fate Therapeutics Reports Fourth Quarter 2020 Financial Results and Highlights Operational Progress GlobeNewswire
03:15PM	Fate Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Feb-22-21 04:01PM	Fate Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference GlobeNewswire -8.37%
Feb-08-21 12:49AM	Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Could Be 26% Below Their Intrinsic Value Estimate Simply Wall St.
Jan-29-21 06:56AM	Got $5,000 and 5 Years to Wait? Buy These 5 Hot Biotech Stocks Now Motley Fool
Jan-28-21 06:42AM	2 Best Biotech Stocks to Buy in January Motley Fool
Jan-11-21 08:02AM	The Zacks Analyst Blog Highlights: Intellia Therapeutics, Editas Medicine, Fate Therapeutic, CRISPR Therapeutics and Vertex Pharmaceuticals Zacks
Jan-08-21 04:26PM	Fate Therapeutics Announces Completion of Public Offering of Common Stock and Pre-Funded Warrants, and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
09:01AM	CRISPR Gene Editing Stocks Up After Intellia's Pipeline Update Zacks

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors, as well as ProTmune for the treatment of hematologic malignancies and rare genetic disorders. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Wolchko J Scott	President and CEO	Apr 22	Option Exercise	2.70	10,000	27,000	441,546	Apr 25 04:11 PM
Wolchko J Scott	President and CEO	Apr 22	Sale	34.59	10,000	345,911	431,546	Apr 25 04:11 PM
Wolchko J Scott	President and CEO	Apr 21	Option Exercise	2.70	30,000	81,000	461,546	Apr 25 04:11 PM
Wolchko J Scott	President and CEO	Apr 21	Sale	35.00	30,000	1,049,881	431,546	Apr 25 04:11 PM
Chu Yu-Waye	Chief Medical Officer	Apr 19	Sale	35.37	4,062	143,673	151,033	Apr 21 04:04 PM
TAHL CINDY	General Counsel and Secretary	Apr 01	Option Exercise	5.22	25,000	130,520	214,151	Apr 04 05:01 PM
TAHL CINDY	General Counsel and Secretary	Apr 01	Sale	38.85	25,000	971,250	189,151	Apr 04 05:01 PM
Valamehr Bahram	Chief R&D Officer	Mar 14	Option Exercise	2.73	25,000	68,250	204,834	Mar 15 04:27 PM
Valamehr Bahram	Chief R&D Officer	Mar 14	Sale	31.07	25,000	776,733	179,834	Mar 15 04:27 PM
MENDLEIN JOHN	Director	Mar 10	Option Exercise	1.63	31,562	51,446	191,017	Mar 11 04:58 PM
MENDLEIN JOHN	Director	Mar 10	Sale	35.02	31,562	1,105,200	159,455	Mar 11 04:58 PM
Wolchko J Scott	President and CEO	Jan 21	Option Exercise	2.70	10,000	27,000	441,546	Jan 24 04:36 PM
Wolchko J Scott	President and CEO	Jan 21	Sale	38.02	10,000	380,200	431,546	Jan 24 04:36 PM
Wolchko J Scott	President and CEO	Jan 20	Option Exercise	2.73	30,000	81,900	461,546	Jan 24 04:36 PM
Wolchko J Scott	President and CEO	Jan 20	Sale	40.21	30,000	1,206,300	431,546	Jan 24 04:36 PM
Wolchko J Scott	President and CEO	Jan 11	Sale	48.68	14,566	709,027	431,546	Jan 13 04:09 PM
TAHL CINDY	General Counsel and Secretary	Jan 11	Sale	48.53	5,419	262,975	155,849	Jan 13 04:08 PM
Dulac Edward J III	Chief Financial Officer	Jan 11	Sale	48.45	1,770	85,757	108,634	Jan 13 04:06 PM
Valamehr Bahram	Chief R&D Officer	Jan 11	Sale	48.50	4,570	221,655	146,532	Jan 13 04:07 PM
Chu Yu-Waye	Senior VP Clinical Development	Jan 11	Sale	48.51	3,965	192,340	121,793	Jan 13 04:05 PM
Wolchko J Scott	President and CEO	Jan 10	Sale	46.86	34,156	1,600,534	446,112	Jan 12 04:07 PM
TAHL CINDY	General Counsel and Secretary	Jan 10	Sale	46.43	7,738	359,313	161,268	Jan 12 04:06 PM
Valamehr Bahram	Chief R&D Officer	Jan 10	Sale	46.38	5,596	259,558	151,102	Jan 12 04:05 PM
TAHL CINDY	General Counsel and Secretary	Jan 03	Option Exercise	6.55	50,000	327,500	219,006	Jan 04 04:03 PM
TAHL CINDY	General Counsel and Secretary	Jan 03	Sale	59.34	50,000	2,966,853	169,006	Jan 04 04:03 PM
Dulac Edward J III	Chief Financial Officer	Dec 20	Option Exercise	35.52	14,437	512,802	126,381	Dec 21 04:08 PM
Dulac Edward J III	Chief Financial Officer	Dec 20	Sale	60.00	15,977	958,620	110,404	Dec 21 04:08 PM
Valamehr Bahram	Chief R&D Officer	Dec 13	Option Exercise	2.73	25,000	68,250	181,698	Dec 14 04:18 PM
Valamehr Bahram	Chief R&D Officer	Dec 13	Sale	47.66	25,000	1,191,406	156,698	Dec 14 04:18 PM
Chu Yu-Waye	Senior VP Clinical Development	Dec 10	Option Exercise	16.32	7,500	122,400	133,258	Dec 13 05:53 PM
Chu Yu-Waye	Senior VP Clinical Development	Dec 10	Sale	51.46	7,500	385,948	125,758	Dec 13 05:53 PM
Wolchko J Scott	President and CEO	Nov 18	Option Exercise	2.70	20,000	54,000	413,793	Nov 22 05:45 PM
Wolchko J Scott	President and CEO	Nov 18	Sale	54.27	20,000	1,085,400	393,793	Nov 22 05:45 PM
Wolchko J Scott	President and CEO	Oct 22	Option Exercise	3.06	30,000	91,670	423,793	Oct 25 04:04 PM
Wolchko J Scott	President and CEO	Oct 22	Sale	58.88	30,000	1,766,400	393,793	Oct 25 04:04 PM
Wolchko J Scott	President and CEO	Oct 21	Option Exercise	2.73	30,000	81,900	423,793	Oct 25 04:04 PM
Wolchko J Scott	President and CEO	Oct 21	Sale	60.22	30,000	1,806,560	393,793	Oct 25 04:04 PM
TAHL CINDY	General Counsel and Secretary	Oct 01	Option Exercise	6.55	50,000	327,500	158,048	Oct 04 04:12 PM
TAHL CINDY	General Counsel and Secretary	Oct 01	Sale	58.83	50,000	2,941,462	108,048	Oct 04 04:12 PM
Dulac Edward J III	Chief Financial Officer	Sep 28	Option Exercise	35.52	17,325	615,384	71,864	Sep 30 04:14 PM
Dulac Edward J III	Chief Financial Officer	Sep 28	Sale	62.53	19,460	1,216,834	52,404	Sep 30 04:14 PM
Valamehr Bahram	Chief Development Officer	Sep 13	Option Exercise	2.73	25,000	68,250	120,740	Sep 14 04:01 PM
Valamehr Bahram	Chief Development Officer	Sep 13	Sale	66.29	25,000	1,657,257	95,740	Sep 14 04:01 PM
Wolchko J Scott	President and CEO	Aug 19	Option Exercise	4.83	20,000	96,700	413,793	Aug 20 04:02 PM
Dulac Edward J III	Chief Financial Officer	Aug 19	Sale	88.26	3,474	306,602	54,539	Aug 20 04:01 PM
Wolchko J Scott	President and CEO	Aug 19	Sale	88.01	20,000	1,760,204	393,793	Aug 20 04:02 PM
Wolchko J Scott	President and CEO	Jul 23	Option Exercise	4.14	30,000	124,100	423,793	Jul 26 04:05 PM
Wolchko J Scott	President and CEO	Jul 23	Sale	85.28	30,000	2,558,538	393,793	Jul 26 04:05 PM
Wolchko J Scott	President and CEO	Jul 22	Option Exercise	2.73	30,000	81,900	423,793	Jul 26 04:05 PM
Wolchko J Scott	President and CEO	Jul 22	Sale	86.05	30,000	2,581,575	393,793	Jul 26 04:05 PM
Valamehr Bahram	Chief Development Officer	Jun 14	Option Exercise	2.84	25,000	70,997	120,740	Jun 16 04:26 PM
Valamehr Bahram	Chief Development Officer	Jun 14	Sale	89.32	25,000	2,233,045	95,740	Jun 16 04:26 PM
Wolchko J Scott	President and CEO	May 20	Option Exercise	4.83	20,000	96,700	413,793	May 24 04:01 PM
Wolchko J Scott	President and CEO	May 20	Sale	77.16	20,000	1,543,292	393,793	May 24 04:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience